Development of transgenic endothelial progenitor cell-seeded stents.

Zhenhua Zhou,Shugui Shi,Mingbao Song,Heqing Huang,Kangning Chen,Jianhong Mi,Lusi Li,Guisheng Chen,Chunli Hou,Guangyu Huang,Chuhong Zhu
DOI: https://doi.org/10.1002/jbm.a.32300
2009-01-01
Journal of Biomedical Materials Research Part A
Abstract:Endothelial progenitor cell (EPC)-seeded intravascular stents may reduce or prevent in-stent restenosis. A20 can play an important role for preventing vascular restenosis. Therefore, it is very important how to enhance the seeding efficiency of A20-modified EPCs on the stent for preventing in-stent restenosis. To approach this problem, we developed a novel transgenic EPC-seeded stent and evaluated its feasibility and efficiency. EPCs were isolated and purified from umbilical blood using immuno-magnetic beads and then transfected with the A20 gene. One stent type (type 1) was coated with EDC cross-linked collagen, and another stent type (type 2) was coated with EDC cross-linked collagen and bound to the CD34 antibody using the bifunctional coupling agent N-succimidyl3-(2-pyridyldithio) propionate (SPDP). Then, the stents were seeded with EPCs transfected with the A20 gene. The stents were implanted in biological artificial vessels, and cell adhesion was determined in a flow chamber. Cell growth was also measured. EPCs were transfected Successfully with the A20 gene. The cells covered both types of stents with favorable biological function. After placement in a flow chamber, the number of cells attached to type I stents significantly dropped and their distribution was scattered. Type 2 stents were basically covered with cells and there were more cells on type 2 stents than on type 1 stents (p < 0.01). Collagen-coupled antibody effectively improves the seeding of transgenic EPCs, offering a new choice of stents to prevent restenosis caused by vascular disease after interventional treatment. (C) 2008 Wiley Periodicals, Inc. J Biomed Mater Res 91A: 623-628, 2009
What problem does this paper attempt to address?